Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

DPP-4 inhibitors offer tolerable treatment option for patients with T2DM

18 Sep 2017

Use of dipeptidyl peptidase 4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus is associated with a lower incidence of gastrointestinal adverse events compared with glucagon-like peptide 1 (GLP-1) receptor agonists, metformin and alpha-glucosidase inhibitors (AGIs), according to a study.

Researchers conducted a systematic review and meta-analysis of 165 randomized controlled trials, involving 122,072 patients, that compared DPP-4 inhibitor–based therapies with placebo and other glucose lowering agents in T2DM. The duration of studies was at least 4 weeks.

Pooled data showed that the incidence of gastrointestinal adverse events did not increase following treatment with DPP-4 inhibitors, including alogliptin (odds ratio [OR], 0.83; 95 percent CI, 0.59 to 1.15), linagliptin (OR, 1.11; 0.92 to 1.35), saxagliptin (OR, 0.96; 0.80 to 1.15), sitagliptin (OR, 0.95; 0.64 to 1.14), teneligliptin (OR, 1.50; 0.81 to 2.77) and vildagliptin (OR, 0.80; 0.63 to 1.01), relative to placebo.

There was a significant reduction in the incidence of gastrointestinal adverse events after treatment with alogliptin (OR, 0.26; 0.15 to 0.44), linagliptin (OR, 0.43; 0.25 to 0.74), saxagliptin (OR, 0.28; 0.17 to 0.46), sitagliptin (OR, 0.24; 0.17 to 0.35) and vildagliptin (OR, 0.27; 0.18 to 0.41) compared with GLP-1 receptor agonists.

Furthermore, DPP-4 inhibitors did not increase the risk of gastrointestinal adverse events relative to metformin and α-glucosidase inhibitors, and had a similar incidence of such events compared with placebo.

The present data suggest that DPP-4 inhibitors represent a tolerable treatment option for patients with T2DM, researchers said.

“For physicians, the efficacy of the medication and adverse effects of the drug must be taken into consideration … in addition to the patient’s comorbidities and history [and] desired route of administration,” they pointed out.

Such consideration is especially important in the management of diabetic patients with gastrointestinal disease, as the gastrointestinal AEs of drugs will negatively affect health-related quality of life, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.